Last updated on February 2019

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent -Thalassemia

Brief description of study

This is a single-arm, open-label, multi-site, single-dose Phase 1/2 study in up to 12 subjects 18 to 35 years of age with transfusion-dependent -thalassemia (TDT), non-0/0. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

Detailed Study Description

The study may be expanded to include up to 45 subjects.

Clinical Study Identifier: NCT03655678

Contact Investigators or Research Sites near you

Start Over

CRISPR Therapeutics Clinical Operations

Research site
Regensburg, Germany
  Connect »

CRISPR Therapeutics Clinical Operations

Research Site
London, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.